darusentan endothelin receptor gilead colorado subsidiary gilead license abbott laboratories developing darusentan potential treatment uncontrolled hypertension june myogen licensed compound abbott application cancer may randomized doubleblind active control parallel assignment safety efficacy phase iii trial initiated subjects completed maintenance period study terminated study reach primary drug article relating cardiovascular system stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikidarusentan